April 7, 2014
Drill Down: Cetuximab and Medical Necessity
Written by Margaret Klasa, DC, APN, Bc
Created on Tuesday, 08 April 2014 12:42
Payment will be recouped when no additional documentation is received from the provider for complex review within the 45-day response period. Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor used for the treatment of metastatic colorectal cancer and head and neck cancer.
The issue references Wisconsin Physicians Service Insurance Corporation’s Local Coverage Determination (LCD): Chemotherapy Drugs and their Adjuncts (L28576) which specifically lists the ICD codes for Cetuximab:
Cetuximab (Erbitux TM) (J9055) 10 mg
Colorectal Cancer 153.0-154.8
Head and Neck Cancer 140.0-149.9, 160.0-161.9, 195.0, 196.0
Non-Small cell lung cancer 162.2-162.9
Squamous Cell Skin Cancer of the head and neck 173.02, 173.12, 173.22, 173.32, 173.42
Squamous Cell Skin Cancer for Regional Recurrences or Distal Metastases 239.2 or V10.83.
Cetuximab is covered when:
-
Used in combination with irinotecan, is indicated for the treatment
of metastatic colorectal carcinoma in patients who are refractory to
irinotecan-based chemotherapy.
-
Administered as a single agent for the treatment of patients with
metastatic colorectal carcinoma in patients who are intolerant to
irinotecan based chemotherapy.
-
The patient must not have K-RAS mutation when using this drug for the treatment of colorectal cancer.
-
As a single agent or in combination with irinotecan after first
progression except in patients receiving capecitabine or fluorouracil
and leucovorin with bevacizumab.
RAC Issues for the Week of April 7 – April 11, 2014:
RAC Region B CGI
Outpatient
-
Cetuximab Medical Necessity OP WPS - A
semi-automated edit to identify potential incorrect billing occurring
for Cetuximab claims billed with an ICD-9-CM code that does not support
medical necessity, according to existing Medicare policy, FDA labeling,
accepted guidelines, approved compendia, or other Medicare rules and
regulations. Payment will be recouped when no additional documentation
is received from the provider for complex review within the 45-day
response period.
DME
-
Suction Catheters for Tracheostomy - CGS - C000362014
- Overpayments were identified where claims billed for suction
catheters were not in accordance with billing requirements outlined in
Local Coverage Determinations.
-
Speech Generating Devices & Accessories - CGS - C004962013
- Medical documentation will be reviewed to determine if the Speech
Generating Device and/or Accessories met coverage indications,
limitations, and/or medical necessity as outlined in CGS LCD.
Dr. Margaret Klasa is the medical director for Context4 Healthcare. She is responsible for the company’s business knowledge discovery unit for medical context as it relates to the daily development of data products and software for medical claims editing and coding, with an emphasis on clinical and regulatory guidelines for Medicare, Medicaid and commercial payers.
Contact the Author
Margaret.Klasa@context4.com
To comment on this article go to editor@racmonitor.com
No comments:
Post a Comment